GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Interest Expense

Scandion Oncology A/S (OSTO:SCOL) Interest Expense : kr0.11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Scandion Oncology A/S's interest expense for the three months ended in Mar. 2024 was kr -0.20 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.11 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Scandion Oncology A/S's Operating Income for the three months ended in Mar. 2024 was kr -15.33 Mil. Scandion Oncology A/S's Interest Expense for the three months ended in Mar. 2024 was kr -0.20 Mil. Scandion Oncology A/S did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Scandion Oncology A/S Interest Expense Historical Data

The historical data trend for Scandion Oncology A/S's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology A/S Interest Expense Chart

Scandion Oncology A/S Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial -0.23 -0.06 -1.06 -0.73 -0.06

Scandion Oncology A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.42 -0.35 1.08 -0.20

Scandion Oncology A/S Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandion Oncology A/S  (OSTO:SCOL) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scandion Oncology A/S's Interest Expense for the three months ended in Mar. 2024 was kr-0.20 Mil. Its Operating Income for the three months ended in Mar. 2024 was kr-15.33 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was kr0.00 Mil.

Scandion Oncology A/S's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Scandion Oncology A/S did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Scandion Oncology A/S (OSTO:SCOL) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines